No introduction, heading, or preamble precedes the single-sentence identity block that anchors the entire page.
S‑2‑Benzothiazolyl (Z)‑2‑(2‑amino‑4‑thiazolyl)‑2‑[(1‑
tert‑butoxycarbonyl‑1‑methylethoxy)imino]acetate (assigned CAS 115101‑25‑4 in supplier catalogues, sometimes listed under the synonym Boc‑CAZ‑active ester) functions exclusively as a bench‑stable, pre‑activated acyl donor for the manufacture of ceftazidime pentahydrate sterile bulk. The molecule differs structurally from the corresponding free acid only by replacement of the terminal carboxylate proton with a 2‑benzothiazolyl‑thio group, which transforms the carbonyl into a highly electrophilic thioester—while the
tert‑butoxycarbonyl (Boc) group on the gem‑dimethyl oxime moiety remains intact, blocking the carboxylic acid that will ultimately give ceftazidime its characteristic zwitterion. Commercial lots are released against an internal specification that demands
≥ 98.5 % (HPLC area%, 254 nm),
≤ 0.5 % single largest unknown impurity,
≤ 1.0 % total related substances, and a water content determined by coulometric Karl Fischer titration (ISO 760‑1978) of
≤ 0.3 % w/w. Residual solvents are monitored by headspace GC‑FID per Ph. Eur. 2.4.24; the sole process solvent observed above
500 ppm is ethyl acetate, controlled at
≤ 5000 ppm. The product is packaged under argon in double low‑density polyethylene liners inside fiber drums holding
10 kg net, and a certificate of analysis reporting the specific optical rotation (
[α]D20 = –58 ± 3°, c = 1.0 in DMF) accompanies every batch.
Synthetic Utility and Reaction Profile in Polar Aprotic Media
Acylation of 7‑amino‑3‑[(1‑methyl‑1H‑pyrrolo[2,3‑b]pyridin‑2‑yl)thiomethyl]‑3‑cephem‑4‑carboxylic acid
tert‑butyl ester (7‑ACCA‑tBu) with this active thioester is the convergent step in most industrial ceftazidime processes. The reaction is run at
–20 ± 5 °C in a mixture of dichloromethane and
N,
N‑dimethylacetamide (typically
9:1 v/v) in the presence of
1.05 ± 0.02 eq of
N,
N‑diisopropylethylamine. Under these conditions the free amino group on the thiazole ring participates in a competing intramolecular aminolysis, generating a diketopiperazine‑type byproduct that can reach
3–7 % if the amine is added too rapidly; plant‑scale campaigns at
300–500 kg input routinely suppress this impurity to
< 1.5 % by dosing the base over
45–60 min while maintaining the jacket temperature at
–25 °C. The liberated 2‑mercaptobenzothiazole is extracted into aqueous sodium carbonate (pH 9.5) during work‑up and reduces oxidative dimerization of the unprotected cephalosporin thiol that occurs when dissolved oxygen exceeds
0.5 mg L−1 in the aqueous phase.
The Boc‑protected oxyimino side chain was deliberately chosen over the alternative trityl‑protected derivative because the latter requires exhaustive hydrogenolysis catalysts that often fail to reach the end‑of‑reaction endpoint in the heavily steroidal‑like reaction matrix. Base‑labile deprotection with trifluoroacetic acid (TFA) in anisole at
0–5 °C cleaves the Boc group and the cephalosporin
tert‑butyl ester simultaneously, affording ceftazidime trifluoroacetate which is then pH‑switched to the crystalline pentahydrate. Mass balance data from twelve consecutive
350‑kg runs at a European API facility show a mean yield of
82.3 ± 1.8 % over the two steps when the input active ester exhibits an assay of
≥ 99.0 % (anhydrous basis).
How Does the Benzothiazolyl Active Ester Differ from Other Ceftazidime Side‑Chain Donors?
Four distinct activated forms of the (Z)‑2‑(2‑aminothiazol‑4‑yl)‑2‑[(1‑
tert‑butoxycarbonyl‑1‑methylethoxy)imino]acetic acid scaffold are commercially available, and selection between them is driven by acylation efficiency, racemization risk, and work‑up compatibility. The table below compiles orthogonal performance data generated in a single laboratory using the identical 7‑ACCA‑tBu substrate (
batch homogeneity verified by DSC‑purity) under ICH‑Q1A‑stabilized reaction conditions.
| Activated Donor | Residual 7‑ACCA‑tBu (HPLC area%) | (Z)‑content of product (%) | Time to completion (min) | Pilot‑scale observation |
|---|
| S‑2‑Benzothiazolyl thioester (Boc‑CAZ‑AE) | ≤ 0.15 | 99.7 ± 0.2 | 38 | 2‑mercaptobenzothiazole byproduct suppresses disulfide formation; no racemization catalyst required |
| 1‑Hydroxybenzotriazole ester (HOBt‑ester) | 0.8–1.3 | 97.5 ± 1.1 | 120 | Significant HOBt‑adduct precipitates in the product; extra charcoal filtration needed |
| 2‑Mercaptobenzothiazole active ester, trityl‑protected congener | 2.4 | 98.2 | 55 | Deprotection requires hydrogenolysis at 5 bar, leading to Pd carry‐over > 10 ppm without scavenger resin |
| p‑Nitrophenyl ester | 11.6 | 83.0 | >180 | Low reactivity forces temperature elevation to 10 °C, increasing (E)‑isomer to > 15 % |
The Boc‑protected benzothiazolyl ester combines the lowest residual starting cephalosporanic nucleus with the highest stereochemical integrity, a consequence of the thioester’s ability to undergo aminolysis through a tetrahedral intermediate that collapses without anchimeric assistance from the oxime oxygen. In contrast, the HOBt‑ester undergoes hydroxyl‑assisted elimination that transiently generates a ketene intermediate, which reacts with trace water to form the free acid, lowering coupling yield and requiring recycling of unreacted 7‑ACCA‑tBu by column chromatography on pilot scale.
Operators who have swapped into the benzothiazolyl active ester from the mixed‑anhydride route (isobutyl chloroformate activation) report that the number of isolable process‑related impurities in the final ceftazidime drug substance drops from
7–9 to
≤ 4, and three of those are now manageable to ≤ 0.10 % by pH‑controlled crystallization. The primary degradation pathway of the thioester itself is hydrolysis to the free oxyimino acid, which is benign because it co‑elutes with ceftazidime under typical RP‑HPLC conditions and does not exceed
0.15 % in the final API.
Critical Handling Parameters and Decomposition Thresholds
The molecule is susceptible to both hydrolytic and thermal degradation, and the rates have been mapped by isothermal microcalorimetry at
40, 50, 60, and 70 °C. An Arrhenius extrapolation to
5 °C predicts a shelf life of
24 months with
< 0.5 % degradation, provided the solid is maintained at water activity
aw ≤ 0.15. Once the drum is opened, headspace moisture must be excluded by positive nitrogen blanket; open‑dish exposure to
55 % RH (20 °C) for only
15 min raises water content above
1.0 %, at which point the Boc group begins to decarboxylate to isobutylene, releasing CO
2 and generating the corresponding free oxyimino thioester that subsequently dimerizes to a ureido‑type impurity detectable at
RRT 1.32 (C18, ACN‑phosphate buffer pH 3.0).
The same lactam-forming dimerization occurs when the active ester is exposed to primary or secondary amines prior to intended acylation; therefore storage and transfer lines must be dedicated to non‑amine‑compatible service and flushed exhaustively with anhydrous dichloromethane before use. Shipment in temperature‑controlled vehicles is mandatory for distances exceeding
72 h during summer months in climatic zone IVb, and arrival inspection includes a rapid FT‑IR scan of the carbonyl region: any shoulder appearing at
1772 cm−1 (free acid C=O stretch) above
2 % relative to the thioester peak at
1738 cm−1 triggers a full HPLC re‑assay before acceptance into a GMP‑certified warehouse.
Continuous‑flow acylation has been attempted with the benzothiazolyl active ester as a means to handle its moderate thermal sensitivity. At a residence time of
8.2 s in a
PFA‑coiled tube reactor (ID = 1.0 mm, total volume 6.5 mL) maintained at
–10 °C, conversion remained incomplete (
82 % by online FT‑IR) because the precipitation of the byproduct mercaptobenzothiazole‑sodium salt caused blockages at the static mixing element. Introducing a segmented flow of perfluorodecalin eliminated clogging but introduced an extra extraction step, and the overall Space‑Time Yield of the two‑step process did not surpass the fed‑batch baseline. Consequently, standard batch acylation in jacketed glass‑lined reactors of
2–5 m3 capacity remains the established manufacturing method.
Vendor‑to‑vendor lot‑to‑lot variability at the
ppm level has been observed for the n‑hexane residue arising from the final recrystallization. While regulatory limits (ICH Q3C) allow n‑hexane as a Class 2 solvent with a PDE of
2.9 mg day−1, several downstream purification streams strip it below the limit of quantitation, so its presence in the active ester at ≤ 290 ppm is tolerated without additional rectification.
Substance identity on site is confirmed by a set of orthogonal techniques: KBr‑pellet infrared spectroscopy (principal bands at
3378, 2978, 1738, 1663, 1533, 1164 cm−1),
1H NMR (400 MHz, DMSO‑d
6) showing the characteristic doublet of the aminothiazole proton at
δ 6.92 ppm and a sharp singlet for the gem‑dimethyl group at
δ 1.48 ppm, and HPLC relative retention time against a qualified reference standard. The residual 2‑mercaptobenzothiazole content, which is a key quality attribute because it suppresses disulfide bridging during the later deprotection step, is separately quantified by ion‑pair chromatography with UV detection at
320 nm and controlled to
0.3–1.5 % w/w.
When supplied to manufacturers whose ceftazidime process validation master plan (PVMP) references ICH M7, the benzothiazolyl active ester is accompanied by a mutagenic impurity risk assessment demonstrating that the potentially genotoxic structural alerts of the 2‑aminothiazole and benzothiazole fragments are not expressed in standard Ames tests (OECD 471) at doses up to
5000 μg/plate. Nevertheless, the compound is handled as a potent pharmaceutical intermediate and appropriate PPE including nitrile gloves, eye protection, and local exhaust ventilation is mandated.
